

Breast cancer survival in Missouri, 2004–2012

Chester Schmaltz, PhD; Kala Visvanathan, MHS, FRACP, PhD; Avonne Connor, MPH, MD; Jeannette Jackson-Thompson, MSPH, PhD

Presenter Disclosures

Chester Schmaltz

(1) The following personal financial relationships with commercial interests relevant to this presentation existed during the past 12 months:

No relationships to disclose

Background

- The Missouri Cancer Registry (MCR) collects
 - population-based cancer incidence and 1st course treatment data on
 - Missouri residents diagnosed with reportable neoplasms
- Complete survival information with follow-up through 31 December 2015.



Background, cont.

 As a preliminary analysis for a project in collaboration with outside researchers at Johns Hopkins University to incorporate comorbidity information from hospital discharge data, MCR analyzed breast cancer (BC) survival.



Purpose

• To present preliminary results on survival using MCR data.



Methods: case selection

- Selected from the MCR database:
 - women age 18+
 - diagnosed with malignant BC
 - Diagnosed between 1 Jan 2004 and 31 Dec 2012
 - Resident of Missouri at diagnosis
- Cases were <u>excluded</u> from the survival analysis that were:
 - diagnosed after death (autopsy / death certificate only cases) or
 - a second or later tumor.



Methods: Cox PH regression

 Cox (proportional hazards) regression was utilized to model the survival,

-Measured in months since diagnosis.

- Three end-points for survival were examined:
 - -death from any cause,
 - -BC death, &
 - -non-BC death.



Methods: modelling

- Covariates include
 - age at diagnosis (modeled with splines),
 - year of diagnosis (modeled with splines),
 - -race,
 - stage at diagnosis,

- grade at diagnosis,
- marital status,
- histology,
- Rural-Urban
 Continuum Code
 2003 (RUCC2003),
- ER/PR status.



Methods: modelling, cont.

 BC-specific survival was additionally analyzed stratified by:

-race (black, white),

- -residence (metro, non-metro), and
- -age group (18-49, 50-59, 60-69, 70+).



Results: any-cause & BCspecific

- For any-cause and BC-specific survival:
 - age and stage were very important predictors for length of survival;
 - -marital status and RUCC2003 were moderately important.



Results: BC-specific



Relative to localized HR (95% CI):

- Regional: 3.3 (3.0, 3.5)
- Distant: 23.3 (21.5, 25.1)

p-values for all factors < .0001, except race (.0005)



Results: BC-specific

 Additionally, for BC-specific survival: low grade and ER+/PR+ status were associated with longer survival.



p-values for all factors < .0001, except race (.0005)



Results: BC-specific

• HR (95% CI) relative to grade I:

- Grade II: 1.7 (1.5, 1.9)
- Grade III: 2.6 (2.3, 2.9)
- Grade IV: 2.4 (1.7, 3.4)
- ... relative to ER+/PR+:
 - ER-/PR-: 1.9 (1.8, 2.0)
 - (ER+/ER- & ER-/PR+ smaller HR, but stat. sig. greater than 1.0)
- ... relative to married:
 - Not married (incl sep): 1.4 (1.3, 1.5)
- ... relative to whites:
 - Black: 1.15 (1.06, 1.24)

p-values for all factors < .0001, except race (.0005)



Results: non-BC

- For non-BC survival, the effect sizes for stage, grade, histology, and ER/PR status were greatly diminished.
 - Not-married effect about same: 1.4 (1.3, 1.5)
 - Black vs white about same: 1.2 (1.1, 1.3)

- HR (95% CI) relative to grade I:
 - (None statistically significantly different from 1.0, type 3 p-value = .8)
 - ... relative to ER+/PR+:
 - (None statistically significantly different from 1.0; type 3 p-value = .03)



Results: non-BC





- Type 3 p-values: •
 - Age, year of dx, stage, marital status, ≤ .0001
 - race:
 - Histology: .001 •
 - ER/PR: .03 •
 - RUCC: .4 •
 - Grade: .8 •





Stratified BC-specific survival

- Each stratified BC-specific analyses by race (black, white), RUCC (metro, non-metro), & age (18–49, 50–59, 60–69, 70+) gave similar* HR estimates for...
 - Stage relative to localized (~3 for regional, ~23 for distant)
 - Grade relative to grade I (~1.7 for grade II, ~2.6 for grade III, ~2.4 for grade IV)
 - Not-married relative to married (~1.4)
 - Receptor status relative to ER+/PR+ (~1.5 for ER+/PR-, ~1.8 for ER-/PR+, ~1.9 for ER-/PR-)
 - Black relative to white (~1.15) (for non-racial stratifications)

* Or didn't differ statistically significantly



Conclusion

- The results of this preliminary analysis:
 - largely cohere with what would have been expected for BC cases;
 - provide a useful baseline in which to compare the results of incorporating comorbid conditions.



Questions?



Chester Lee Schmaltz, PhD

Senior Statistician Missouri Cancer Registry and Research Center Adjunct Assistant Professor Health Management & Informatics

401 Clark Hall University of Missouri, School of Medicine Columbia MO 65211–4380

573–882–7775 <u>SchmaltzC@Missouri.edu</u> <u>http://mcr.umh.edu</u>

This project was supported in part by an agreement between MU and **Johns** Hopkins University (JHU) and a grant from the Women's Foundation of Kansas City, MO to JHU.



I would like to thank MCR-ARC Quality Assurance staff and the staff of facilities throughout Missouri and other states' central cancer registries for their dedication and desire for continuous quality improvement and submitting their reportable cases to MCR-ARC.

MCR-ARC core activities are supported in part by a cooperative agreement between the Centers for Disease Control and Prevention (CDC) and the Missouri Department of Health and Senior Services (DHSS) (U58/DP006299-01 / -02) and a Surveillance Contract between DHSS and the University of Missouri (MU).